<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573491</url>
  </required_header>
  <id_info>
    <org_study_id>IMP-CYP SA HF 2020-001</org_study_id>
    <nct_id>NCT04573491</nct_id>
  </id_info>
  <brief_title>Implementation of Pharmacogenetic Testing in Hospital Wards</brief_title>
  <acronym>FAGLIS</acronym>
  <official_title>Implementation of Pharmacogenetic Testing as Part of Medication Reviews in Hospital Wards</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Pharmacy Enterprise, South Eastern Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Pharmacy Enterprise, South Eastern Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether it is feasible to implement&#xD;
      pharmacogenetic testing as part of medication review while the patient is admitted to&#xD;
      hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the&#xD;
      efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of&#xD;
      pharmacogenetic testing as part of medication reviews reveals more serious drug related&#xD;
      problems and leads to more changes in medication treatment than medication review alone.&#xD;
&#xD;
      The use of pharmacogenetic testing as part of medication reviews has not earlier been&#xD;
      systematically investigated in hospital patients in Norway. There is little documentation of&#xD;
      what is needed to implement the use of pharmacogenetic testing in a hospital ward.&#xD;
&#xD;
      The investigators are conducting a descriptive study in two internal medicine wards at&#xD;
      Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least&#xD;
      one relevant for pharmacogenetic testing will be enrolled in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with results from pharmacogenetic testing included in medication review</measure>
    <time_frame>from admission to discharge, an average of 1 week</time_frame>
    <description>Number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptance of recommendations</measure>
    <time_frame>after medication review and before discharge, an average of 3 days</time_frame>
    <description>Degree of acceptance of recommendations after pharmacogenetic testing, by prescribers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of information from pharmacogenetic testing</measure>
    <time_frame>after medication review and before discharge, an average of 3 days</time_frame>
    <description>Number of patients with information from pharmacogenetic testing documented in the patient journal</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Admitted Multimorbid Patients</condition>
  <arm_group>
    <arm_group_label>Pharmacogenetic test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medication review including results from pharmacogenetic testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Pharmacogenetic test</intervention_name>
    <description>genotyping for genes that affect drug metabolism</description>
    <arm_group_label>Pharmacogenetic test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication review</intervention_name>
    <description>systematic and interdisciplinary method aiming to increase quality of medication treatment</description>
    <arm_group_label>Pharmacogenetic test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 2 long-term conditions&#xD;
&#xD;
          -  at least 5 regular drugs of which at least one relevant for pharmacogenetic testing&#xD;
&#xD;
          -  at least 2 years life expectancy&#xD;
&#xD;
          -  able to communicate in Norwegian&#xD;
&#xD;
          -  able to give informed consent&#xD;
&#xD;
          -  summary care record&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  moderate to severe dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrin Bjerknes, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Pharmacy Enterprise, South Eastern Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathrin Bjerknes, Ph.D</last_name>
    <phone>+4767960304</phone>
    <email>kathrin.bjerknes@sykehusapotekene.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bodil J Hjemås, M.Sc.Pharm</last_name>
    <phone>+4767960302</phone>
    <email>bodil.jahren.hjemas@sykehusapotekene.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Nordbyhagen</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathrin Bjerknes, Ph.D</last_name>
      <phone>+4767960304</phone>
      <email>kathrin.bjerknes@sykehusapotekene.no</email>
    </contact>
    <contact_backup>
      <last_name>Bodil J Hjemås, M.Sc.Pharm</last_name>
      <phone>+4767960302</phone>
      <email>bodil.jahren.hjemas@sykehusapotekene.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenetics</keyword>
  <keyword>implementation</keyword>
  <keyword>medication review</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

